Elevated circulating PCSK9 level is associated with 28-day mortality in patients with sepsis: a prospective cohort study

Abstract

Objectives Pro-protein convertase subtilisin/kexin 9 (PCSK9) decreases the clearance of the pathogenic lipids, supporting the potential role of PCSK9 in the prognosis of sepsis. Methods In this prospective cohort study, patients with sepsis were consecutively recruited from 1 to 2020 to 30 September 2021 at the First People’s Hospital of Huaihua, China. All the eligible patients were categorized into low-PCSK9 and high-PCSK9 groups, based on their PCSK9 levels at admission. Time-dependent receiver operating characteristic curves and Cox proportional hazards regression were used to evaluate the association between PCSK9 level and 28-day mortality of sepsis. Results Of the 203 enrolled patients, 56 (27.59%) died during the 28-day follow-up. The PCSK9 level was positively related to the C-reactive protein level. The cut-off point of PCSK9 levels for 28-day mortality risk was 370 ng/ml. Through comparison between high-PCSK9 (> 370 ng/ml) with low-PCSK9 (≤ 370 ng/ml) groups, the adjusted HR for mortality was 2.56 (95% CI: 1.25–5.23, p = 0.01). Conclusions The 28-day mortality of sepsis increased significantly as the baseline circulating PCSK9 level exceeded 370 ng/ml, indicating circulating PCSK9 levels may be a potential biomarker to predict the prognosis of sepsis.

Assessment of serum proprotein convertase subtilisin/kexin type 9 in pediatric sepsis syndrome

“…It has been demonstrated that subjects with at least one loss of function (LOF) PCSK9 allele were more likely to survive, whereas subjects carrying the gain-of-function (GOF) allele were less likely to survive 26 . Moreover, a study by Shu and his coworkers in 2023 reported that the 28-day mortality of sepsis increased significantly as the baseline circulating PCSK9 level exceeded 370 ng/ml in their patients, indicating circulating PCSK9 levels may be a potential biomarker to predict the prognosis of sepsis 29 .…”